European Union - Latvian - EMA (European Medicines Agency)

astrazeneca ab - selumetinib sulfate - neurofibromatosis 1 - antineoplastiski līdzekļi - koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (pn) in paediatric patients with neurofibromatosis type 1 (nf1) aged 3 years and above.

European Union - Latvian - EMA (European Medicines Agency)

oncopeptides ab - melphalan flufenamide hydrochloride - multiple mieloma - antineoplastiski līdzekļi - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.

European Union - Latvian - EMA (European Medicines Agency)

amryt pharmaceuticals dac - octreotide acetate - akromegālija - hipofīzes un hipotalāma hormoni un analogi - mycapssa is indicated for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.

European Union - Latvian - EMA (European Medicines Agency)

mirum pharmaceuticals international b.v. - maralixibat chloride - alagille syndrome - citas zāles žults sistēmas slimību ārstēšanai - livmarli is indicated for the treatment of cholestatic pruritus in patients with alagille syndrome (algs) 2 months of age and older.

Latvia - Latvian - Zāļu valsts aģentūra

g.l. pharma gmbh, austria - morfīna hidrohlorīds - ilgstošās darbības tablete - 60 mg

Latvia - Latvian - Zāļu valsts aģentūra

g.l. pharma gmbh, austria - morfīna hidrohlorīds - ilgstošās darbības tablete - 100 mg

Latvia - Latvian - Zāļu valsts aģentūra

g.l. pharma gmbh, austria - morfīna hidrohlorīds - ilgstošās darbības tablete - 10 mg

Latvia - Latvian - Zāļu valsts aģentūra

g.l. pharma gmbh, austria - morfīna hidrohlorīds - ilgstošās darbības tablete - 30 mg

Latvia - Latvian - Zāļu valsts aģentūra

kalceks, a/s, latvia - morfīna hidrohlorīds - Šķīdums injekcijām - 10 mg/ml

Latvia - Latvian - Zāļu valsts aģentūra

kalceks, a/s, latvia - morfīna hidrohlorīds - Šķīdums injekcijām/infūzijām - 20 mg/ml